Kymera Therapeutics (NASDAQ: KYMR) reported Q4 EPS of ($0.25), $0.15 better than the analyst estimate of ($0.40). Revenue for the quarter came in at $47.9 million versus the consensus estimate of $41.94 million.

For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.